ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements with these filters
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
Indegene Limited shareholders approved the appointment of Ms. Jill Mary De Simone as an Independent Director for a three-year term starting January 22, 2026.
Indegene Ltd held its 28th Annual General Meeting on August 13, 2026. The meeting transacted business including dividend declaration and appointment of directors.
BPC Genesis Fund I SPV Limited, a non-promoter entity, sold its entire 5.757% stake in Indegene Limited. The open market transaction involved 13,862,223 equity shares.
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene Limited allotted 12,451 equity shares under its ESOP scheme. This allotment marginally increases the company's paid-up share capital.
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene reported strong Q1 FY27 results with revenue of ₹1,063.1 Crore, up 39.7% YoY. EBITDA rose to ₹179.5 Crore with a 16.9% margin.
Indegene Limited filed its Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of its IPO proceeds.
Indegene Ltd reported revenue from operations of ₹1,063 Cr (+39.7% YoY) and net profit of ₹116.2 Cr (-0.2% YoY) for Q1 FY27.
Indegene Limited scheduled its 28th AGM for August 13, 2026. Key agenda items include declaring a Rs 2.25 per share dividend and director appointments.
Indegene Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance and adherence to NGRBC principles.
Indegene Limited fixed July 31, 2026, as the record date for its ₹2.25 per share final dividend. The 28th AGM is scheduled for August 13, 2026.
Indegene Ltd announces a board meeting on 30 July 2026 to approve unaudited Q2 results and ESOP/RSU allotments. Trading window will resume after results release.
Indegene Limited disclosed under SEBI takeover regulations that it has no identifiable promoter for FY2025-26. Investors are informed of the company's promoter-less status.
Indegene Limited allotted 52,951 equity shares following the exercise of employee stock options. This marginally increases the paid-up capital to ₹48.19 Crore.
Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.
Indegene positions as an AI-embedded operating partner for life sciences. Reported FY26 revenue of INR 35.1Bn with 19.4% EBITDA margins and 29.4% CAGR.
Indegene crossed ₹1,000Cr quarterly revenue milestone in Q4FY26. Strategy focuses on GenAI-led transformation (Tectonic model) and deepening top-20 global pharma relationships.
Indegene Ltd received a ₹43.69 Crore income tax demand notice for Assessment Year 2023-24. The demand arises from transfer pricing adjustments. The company is pursuing resolution through the Mutual Agreement Procedure (MAP) and domestic appellate remedies, and does not expect a material adverse impact on its financial position.
Indegene Limited has been identified as a 'Leader' by Information Services Group (ISG) for Life Sciences Digital Services in Commercial Operations. The recognition highlights Indegene's domain expertise and proprietary AI-led technology platforms. This marks the third consecutive year the company has achieved this leadership ranking, reinforcing its position as a trusted partner in life sciences.
Indegene crossed the ₹1000cr quarterly revenue milestone for the first time in Q4FY26, though PAT was slightly dragged by exceptional legal provisions.
Indegene Limited submitted its Monitoring Agency Report for the quarter ended March 31, 2026, regarding its ₹760 Crore IPO proceeds. The report, issued by CareEdge Ratings, confirms the utilization status towards stated objects, including debt repayment and capital expenditure. The monitoring agency noted some delays in fund deployment and reallocations approved via special resolutions.
Indegene Limited confirmed its status as a non-Large Corporate for the financial year 2026-27. The company reported zero outstanding borrowings as of March 31, 2026, exempting it from mandatory incremental borrowing through debt securities under SEBI's large corporate framework.
Indegene Limited recommended a final dividend of 112.5 per equity share for the period ended April 29, 2026. The record date and general meeting date for shareholder approval will be communicated later. This announcement follows the board meeting concluded on April 29, 2026.